Zuranolone

Abstract

Zuranolone is an oral neuroactive steroid under development by Sage Therapeutics and Biogen (SAGE-217/BIIB125). It is currently being evaluated as a treatment option for postpartum depression (PPD) and major depressive disorder (MDD). MDD is one of the most frequent mental disorders; for example, in the United States, it affects more than 8 % of adults every year. On the other hand, PPD is one of the most common medical complications during and after pregnancy and is estimated to affect approximately one in eight women who have given birth. Although clinical presentation of MDD and PPD varies, patients frequently experience feelings of hopelessness, anxiety or sadness which, consequently, affect their quality of life, in terms of ability to work, maintenance of relationships and school attendance. In severe cases, risk of suicide can be substantial. As for the treatment of these disorders, current guidelines include a multitude of approved antidepressants which can help alleviate symptoms for most patients. However, these medications in general require four to six weeks to work. In translation that means patients must endure their symptoms for a month or more after starting a treatment to see if it helps.